Katano Atsuto, Takenaka Ryousuke, Yamashita Hideomi, Ando Mizuo, Yoshida Masafumi, Saito Yuki, Asakage Takahiro, Abe Osamu, Nakagawa Keiichi
Department of Radiology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo 113-8655, Japan.
Department of Otolaryngology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo 113-8655, Japan.
Mol Clin Oncol. 2021 Mar;14(3):45. doi: 10.3892/mco.2021.2207. Epub 2021 Jan 13.
External auditory canal carcinoma (EACC) is a rare disease. The current study aimed to evaluate the clinical outcomes of patients treated with external beam radiotherapy (EBRT) for EACC. The present study retrospectively reviewed 34 consecutive patients treated for EACC with EBRT between February 2001 and January 2019 at the University of Tokyo Hospital. Clinical staging was performed according to the modified Pittsburgh classification. Of all the included patients, seven patients were in the early stages (I or II) and 27 in the advanced stages (III or IV) of EACC. A total of 16 patients underwent EBRT and surgery (S+RT) pre- and/or postoperatively, while 18 patients underwent definitive radiotherapy (dRT). The median prescribed doses for the S+RT and dRT groups were 66 and 70 Gy, respectively. The median follow-up period for all patients was 22.4 months (range, 2-205 months). The 5-year overall survival rates of the S+RT and dRT groups were 66.7 and 45.1%, respectively. The progression-free survival rate at 5-year was 55.6% (95% confidence interval: 36.5-71.1%) for the entire cohort. A total of 14 patients experienced disease relapse after treatment, consisting of 11 locoregional recurrences and three distant metastases. The current study revealed the clinical outcomes of EBRT for EACC.
外耳道癌（EACC）是一种罕见疾病。本研究旨在评估接受外照射放疗（EBRT）治疗的外耳道癌患者的临床结局。本研究回顾性分析了2001年2月至2019年1月期间在东京大学医院连续接受EBRT治疗的34例外耳道癌患者。根据改良的匹兹堡分类法进行临床分期。在所有纳入的患者中，7例处于外耳道癌早期（I期或II期），27例处于晚期（III期或IV期）。共有16例患者在术前和/或术后接受了EBRT和手术（S+RT），18例患者接受了根治性放疗（dRT）。S+RT组和dRT组的中位处方剂量分别为66 Gy和70 Gy。所有患者的中位随访期为22.4个月（范围：2 - 205个月）。S+RT组和dRT组的5年总生存率分别为66.7%和45.1%。整个队列的5年无进展生存率为55.6%（95%置信区间：36.5 - 71.1%）。共有14例患者在治疗后出现疾病复发，包括11例局部区域复发和3例远处转移。本研究揭示了EBRT治疗外耳道癌的临床结局。
